The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

sulfurothioic S-acid     sulfurothioic S-acid

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of sulfurothioic S-acid


Psychiatry related information on sulfurothioic S-acid


High impact information on sulfurothioic S-acid


Chemical compound and disease context of sulfurothioic S-acid


Biological context of sulfurothioic S-acid


Anatomical context of sulfurothioic S-acid

  • Analysis of genomic DNA from different muscle cell populations allowed the assignment of one marker to the muscle (Hypo A) lineage and the other, more tentatively, to the 'connective tissue' (Hypo B) component of muscle [20].
  • Pretreatment thyroid volume in the Eu-group and Hyper-group was significantly greater (P = 0.009) than in the Hypo-group [21].
  • Hypo-osmotic shocks induced a reversible depolarization of muscle cells but which was not affected by amiloride [22].
  • Dextran also inhibited both mitochondrial oxidation of exogenous ferrocytochrome c in the presence of rotenone and antimycin, and respiratory-chain-driven reduction of exogenous ferricytochrome c. Hypo-osmotic medium or digitonin treatment of mitochondria caused a large additional release of both cytochrome c and AK that was not blocked by dextran [23].
  • BACKGROUND: Hypo-activation of the left dorsolateral prefrontal cortex is inconsistently found in neuroimaging studies of schizophrenia [24].

Associations of sulfurothioic S-acid with other chemical compounds


Gene context of sulfurothioic S-acid

  • Hypo-osmotic swelling of human Intestine 407 cells leads to a significant increase of intracellular MAPKAP-kinase 2 activity and Hsp27 phosphorylation [30].
  • Hypo-osmotic treatment (205 mosmol/l) led to an increased activity of Erk-1 and Erk-2 within 3 min, which became maximal at 10 min and returned to basal level within 120 min [31].
  • Hypo-osmotic cell swelling activates the p38 MAP kinase signalling cascade [30].
  • Hypo-responsiveness of the 5-HT1A receptor is linked to anxiety and constitutive deletion of the 5-HT1A receptor produces anxiety-like behaviors in the mouse [32].
  • CONCLUSION: Hypo-methylating agents may be useful in the treatment of patients having ccRCC tumors consisting of cells with methylated VHL [33].

Analytical, diagnostic and therapeutic context of sulfurothioic S-acid


  1. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. Goel, R., Cleary, S.M., Horton, C., Kirmani, S., Abramson, I., Kelly, C., Howell, S.B. J. Natl. Cancer Inst. (1989) [Pubmed]
  2. Efficacy of two-route chemotherapy using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, in combination with angiotensin II in a rat limb tumor. Kuroiwa, T., Aoki, K., Taniguchi, S., Hasuda, K., Baba, T. Cancer Res. (1987) [Pubmed]
  3. BOLD signal increase preceeds EEG spike activity--a dynamic penicillin induced focal epilepsy in deep anesthesia. Mäkiranta, M., Ruohonen, J., Suominen, K., Niinimäki, J., Sonkajärvi, E., Kiviniemi, V., Seppänen, T., Alahuhta, S., Jäntti, V., Tervonen, O. Neuroimage (2005) [Pubmed]
  4. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Doolittle, N.D., Muldoon, L.L., Brummett, R.E., Tyson, R.M., Lacy, C., Bubalo, J.S., Kraemer, D.F., Heinrich, M.C., Henry, J.A., Neuwelt, E.A. Clin. Cancer Res. (2001) [Pubmed]
  5. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Tegeder, I., Bräutigam, L., Seegel, M., Al-Dam, A., Turowski, B., Geisslinger, G., Kovács, A.F. Clin. Pharmacol. Ther. (2003) [Pubmed]
  6. Hypo- and hyperresponders: individual differences in the response of serum cholesterol concentration to changes in diet. Beynen, A.C., Katan, M.B., Van Zutphen, L.F. Adv. Lipid Res. (1987) [Pubmed]
  7. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. Tan, P., Anasetti, C., Hansen, J.A., Melrose, J., Brunvand, M., Bradshaw, J., Ledbetter, J.A., Linsley, P.S. J. Exp. Med. (1993) [Pubmed]
  8. Differential sub-cellular compartmentalization of thyrotropin releasing hormone (TRH) and gonadotropin releasing hormone (LRH) in hypothalamic tissue. Barnea, A., Ben-Jonathan, N., Colston, C., Johnston, J.M., Porter, J.C. Proc. Natl. Acad. Sci. U.S.A. (1975) [Pubmed]
  9. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Neuwelt, E.A., Pagel, M.A., Hasler, B.P., Deloughery, T.G., Muldoon, L.L. Cancer Res. (2001) [Pubmed]
  10. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Neuwelt, E.A., Brummett, R.E., Remsen, L.G., Kroll, R.A., Pagel, M.A., McCormick, C.I., Guitjens, S., Muldoon, L.L. Cancer Res. (1996) [Pubmed]
  11. Chemotherapy administered using two-route infusion of cisplatin and sodium thiosulfate and intravenous infusion of vinblastine and peplomycin in patients with oral cancer. Wada, T., Harada, M., Morita, N., Oomata, T., Koizumi, T., Kawashima, T., Sakamoto, T. Clinical therapeutics. (1995) [Pubmed]
  12. Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity in the mouse. Dorr, R.T., Soble, M., Alberts, D.S. Cancer Chemother. Pharmacol. (1988) [Pubmed]
  13. Evaluation of cis-diamminedichloroplatinum(II) combined with metoclopramide or sodium thiosulfate on L1210 leukemia in vitro and in vivo. Catino, J.J., Francher, D.M., Schurig, J.E. Cancer Chemother. Pharmacol. (1986) [Pubmed]
  14. Mixotrophic and heterotrophic growth of Beggiatoa alba in continuous culture. Güde, H., Strohl, W.R., Larkin, J.M. Arch. Microbiol. (1981) [Pubmed]
  15. The effects of sulfur, thiol, and thiol inhibitor compounds on arsine-induced toxicity in the human erythrocyte membrane. Rael, L.T., Ayala-Fierro, F., Carter, D.E. Toxicol. Sci. (2000) [Pubmed]
  16. Inhibition of beta-propiolactone-induced mutagenesis and neoplasia by sodium thiosulfate. Wattenberg, L.W., Hochalter, J.B., Galbraith, A.R. Cancer Res. (1987) [Pubmed]
  17. Activation of the osmo-sensitive chloride conductance involves P21rho and is accompanied by a transient reorganization of the F-actin cytoskeleton. Tilly, B.C., Edixhoven, M.J., Tertoolen, L.G., Morii, N., Saitoh, Y., Narumiya, S., de Jonge, H.R. Mol. Biol. Cell (1996) [Pubmed]
  18. Multiple oral doses of nicardipine, a calcium-entry blocker: effects on renal function, plasma renin activity, and aldosterone concentration in mild-to-moderate essential hypertension. Baba, T., Ishizaki, T., Murabayashi, S., Aoyagi, K., Tamasawa, N., Takebe, K. Clin. Pharmacol. Ther. (1987) [Pubmed]
  19. Hypo-active variant of IL-2 and associated decreased T cell activation contribute to impaired apoptosis in autoimmune prone MRL mice. Choi, Y., Simon-Stoos, K., Puck, J.M. Eur. J. Immunol. (2002) [Pubmed]
  20. Evidence for dedifferentiation and metaplasia in amphibian limb regeneration from inheritance of DNA methylation. Casimir, C.M., Gates, P.B., Patient, R.K., Brockes, J.P. Development (1988) [Pubmed]
  21. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. Chiovato, L., Fiore, E., Vitti, P., Rocchi, R., Rago, T., Dokic, D., Latrofa, F., Mammoli, C., Lippi, F., Ceccarelli, C., Pinchera, A. J. Clin. Endocrinol. Metab. (1998) [Pubmed]
  22. Patch clamp study of the UNC-105 degenerin and its interaction with the LET-2 collagen in Caenorhabditis elegans muscle. Jospin, M., Mariol, M.C., Segalat, L., Allard, B. J. Physiol. (Lond.) (2004) [Pubmed]
  23. Cytochrome c release from isolated rat liver mitochondria can occur independently of outer-membrane rupture: possible role of contact sites. Doran, E., Halestrap, A.P. Biochem. J. (2000) [Pubmed]
  24. Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia. Spence, S.A., Hirsch, S.R., Brooks, D.J., Grasby, P.M. The British journal of psychiatry : the journal of mental science. (1998) [Pubmed]
  25. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. Robbins, K.T., Storniolo, A.M., Kerber, C., Vicario, D., Seagren, S., Shea, M., Hanchett, C., Los, G., Howell, S.B. J. Clin. Oncol. (1994) [Pubmed]
  26. Systemic chemotherapy in tumor-bearing rats using high-dose cis-diamminedichloroplatinum(II) with low nephrotoxicity in combination with angiotensin II and sodium thiosulfate. Kobayashi, H., Hasuda, K., Aoki, K., Taniguchi, S., Baba, T. Int. J. Cancer (1990) [Pubmed]
  27. Inactivation of cis-diamminedichloroplatinum (II) in blood by sodium thiosulfate. Abe, R., Akiyoshi, T., Baba, T. Oncology (1990) [Pubmed]
  28. Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. Neuwelt, E.A., Pagel, M.A., Kraemer, D.F., Peterson, D.R., Muldoon, L.L. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  29. Systemic therapy emergencies. Albanell, J., Baselga, J. Semin. Oncol. (2000) [Pubmed]
  30. Hypo-osmotic cell swelling activates the p38 MAP kinase signalling cascade. Tilly, B.C., Gaestel, M., Engel, K., Edixhoven, M.J., de Jonge, H.R. FEBS Lett. (1996) [Pubmed]
  31. Osmosignalling in C6 glioma cells. Sinning, R., Schliess, F., Kubitz, R., Häussinger, D. FEBS Lett. (1997) [Pubmed]
  32. Differential effects of 5-HT1A receptor deletion upon basal and fluoxetine-evoked 5-HT concentrations as revealed by in vivo microdialysis. He, M., Sibille, E., Benjamin, D., Toth, M., Shippenberg, T. Brain Res. (2001) [Pubmed]
  33. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine. Alleman, W.G., Tabios, R.L., Chandramouli, G.V., Aprelikova, O.N., Torres-Cabala, C., Mendoza, A., Rogers, C., Rodgers, C., Sopko, N.A., Linehan, W.M., Vasselli, J.R. Clin. Cancer Res. (2004) [Pubmed]
  34. Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Zimm, S., Cleary, S.M., Lucas, W.E., Weiss, R.J., Markman, M., Andrews, P.A., Schiefer, M.A., Kim, S., Horton, C., Howell, S.B. Cancer Res. (1987) [Pubmed]
  35. Intraperitoneal cis-diamminedichloroplatinum with systemic thiosulfate protection. Howell, S.B., Pfeifle, C.E., Wung, W.E., Olshen, R.A. Cancer Res. (1983) [Pubmed]
  36. Clinical pharmacokinetics of intraarterial cisplatin in humans. Campbell, T.N., Howell, S.B., Pfeifle, C.E., Wung, W.E., Bookstein, J. J. Clin. Oncol. (1983) [Pubmed]
  37. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Muldoon, L.L., Pagel, M.A., Kroll, R.A., Brummett, R.E., Doolittle, N.D., Zuhowski, E.G., Egorin, M.J., Neuwelt, E.A. Clin. Cancer Res. (2000) [Pubmed]
  38. NMR spectroscopic characterization of sarcolemmal permeability during myocardial ischemia and reperfusion. Askenasy, N., Vivi, A., Tassini, M., Navon, G., Farkas, D.L. J. Mol. Cell. Cardiol. (2001) [Pubmed]
WikiGenes - Universities